Expression data of AML cells treated with out without H4

Safer and more efficient therapy for patients with acute myeloid leukemia (AML) is needed and differentiation therapy is an appealing option to eradicate leukemic stem cells blocked in differentiation. With the aim of identifying new AML differentiating agents/molecules, we screened 528 natural compounds on primary AML samples. Compounds that upregulated the expression of the myeloid differentiation markers CD11b/CD15 were considered as positive hits. Among those, a macrocyclic diterpenecalled H4 upregulated expression of CD11b (DMSO 22±5%, H4 66±8% SEM), which was accompanied with a clear decrease in nuclear-cytoplasmic ratio, on patient cells with AML subtype M5. To identify the mechansim AML cells were treated with H4 for 16 hrs followed by gene expression analysis. Comparing primary acute Myeloid leukemia traeated with the H4 molecule